You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

il-2

Showing 26 - 50 of 60
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Carcinoma, Renal Cell Trial in Houston (TroVax, IL-2)

Completed
  • Carcinoma, Renal Cell
  • TroVax
  • IL-2
  • Houston, Texas
    The Methodist Hospital
Oct 9, 2020

Acute Myeloid Leukemia, Leukemia, Myeloid Leukemia Trial in Spain (cyclophosphamide, Fludarabine, NK cell infusion)

Completed
  • Acute Myeloid Leukemia
  • +2 more
  • Barakaldo, Vizcaya, Spain
  • +5 more
Oct 1, 2020

Ewing's Sarcoma, Rhabdomyosarcoma Trial run by the NCI (EF-1 Peptide, EF-2 Peptide, PXFK Peptide)

Completed
  • Ewing's Sarcoma
  • Rhabdomyosarcoma
  • EF-1 Peptide
  • +7 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Nov 27, 2019

Lymphoma, B-cell Lymphoma Trial in Houston (Leukapheresis, Stem Cell Transplant, CD19-specific T Cell Infusion)

Completed
  • Lymphoma
  • B-cell Lymphoma
  • Leukapheresis
  • +7 more
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Jun 27, 2020

Infection in Treatment of Low-dose IL-2 of SLE Patients

Unknown status
  • Infection
  • IL-2
  • Beijing, Beijing, China
    Peking Universtiy People's Hospital
Oct 21, 2019

Metastatic Renal Cell Carcinoma Trial in United States (Hydroxychloroquine, IL-2)

Completed
Has Results
  • Metastatic Renal Cell Carcinoma
  • Maywood, Illinois
  • +6 more
Dec 24, 2019

Melanoma Trial in Houston (Vemurafenib, IL-2, Interferon Alpha-2b)

Completed
  • Melanoma
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
May 17, 2019

Metastatic Renal Cell Carcinoma Trial (PD-1 Knockout T Cells, Cyclophosphamide, IL-2)

Withdrawn
  • Metastatic Renal Cell Carcinoma
  • PD-1 Knockout T Cells
  • +2 more
  • (no location specified)
Mar 4, 2019

PD-1 Knockout Engineered T Cells for Castration Resistant

Withdrawn
  • Hormone Refractory Prostate Cancer
  • PD-1 Knockout T Cells
  • +2 more
  • Beijing, Beijing, China
    Department of Urology Peking University First Hospital
Mar 4, 2019

Invasive Bladder Cancer Stage IV Trial in Beijing (PD-1 Knockout T Cells, Cyclophosphamide, IL-2)

Withdrawn
  • Invasive Bladder Cancer Stage IV
  • PD-1 Knockout T Cells
  • +2 more
  • Beijing, Beijing, China
    Department of Urology Peking University First Hospital
Mar 4, 2019

Malignant Melanoma Stage IV Trial in Ramat Gan (Fludarabine, Cyclophosphamide, TIL)

Unknown status
  • Malignant Melanoma Stage IV
  • Ramat Gan, Israel
    Sheba Medical Center
Apr 3, 2019

Metastatic Ovarian Cancer Trial in Ramat Gan (drug, radiation, biological)

Unknown status
  • Metastatic Ovarian Cancer
  • Ramat Gan, Israel
    Sheba medical Center
Apr 3, 2019

Depression Trial in Atlanta (Escitalopram, Placebo, IL-2)

Completed
Has Results
  • Depression
  • Atlanta, Georgia
    Winship Cancer Institute
Aug 13, 2018

Metastatic Colorectal Cancer Trial in Fuzhou (Irinotecan, Oxaliplatin, Levoleucovorin)

Withdrawn
  • Metastatic Colorectal Cancer
  • Fuzhou, Fujian, China
    Rongbo Lin
Mar 23, 2018

Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma Trial in Lebanon (GM-CSF, IL-2)

Completed
  • Non-Hodgkin's Lymphoma
  • +4 more
  • Lebanon, New Hampshire
    Dartmouth-Hitchcock Medical Center
Apr 23, 2018

Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer Trial in Minneapolis (Fludarabine, Cyclophosphamide,

Completed
Has Results
  • Ovarian Cancer
  • +3 more
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Dec 3, 2017

Hepatocellular Carcinoma Trial in Beijing (iNKT cells, IL-2, Tegafur)

Unknown status
  • Hepatocellular Carcinoma
  • iNKT cells
  • +2 more
  • Beijing, Beijing, China
    Beijing Youan Hospital,Capital Medical University
Jan 17, 2018

Hepatocellular Carcinoma Trial in Beijing (HCC antigens-specific CD8+ T lymphocytes, IL-2, Tegafur)

Unknown status
  • Hepatocellular Carcinoma
  • HCC antigens-specific CD8+ T lymphocytes
  • +2 more
  • Beijing, Beijing, China
    Beijing Youan Hospital,Capital Medical University
Jan 17, 2018

Leukemia, Myelogenous, Acute Trial in Minneapolis (biological, drug, procedure)

Terminated
Has Results
  • Leukemia, Myelogenous, Acute
  • Natural Killer Cells
  • +5 more
  • Minneapolis, Minnesota
    Masonic Cancer Center, University of Minnesota
Dec 3, 2017

Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma Trial in Minneapolis (Fludarabine, Cyclophosphamide, NK

Completed
  • Ovarian Cancer
  • +2 more
  • Minneapolis, Minnesota
    University of Minnesota Masonic Cancer Center
Dec 3, 2017

Graft-Versus-Host-Disease Trial in Tampa (IL-2, Tacrolimus, Sirolimus)

Completed
Has Results
  • Graft-Versus-Host-Disease
  • IL-2
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jun 1, 2017

Kidney Cancer Trial run by the NCI (117-126:Fibroblast growth factor 5 (FGF-5), Fibroblast growth factor 5

Terminated
Has Results
  • Kidney Cancer
  • 117-126:Fibroblast growth factor 5 (FGF-5)
  • +2 more
  • Bethesda, Maryland
    National Cancer Institute (NCI)
Jul 3, 2017

Neuroblastoma, Lymphoma, High-risk Tumor Trial in Memphis (biological, drug, device)

Completed
  • Neuroblastoma
  • +2 more
  • CD133+ selected autologous stem cell infusion
  • +13 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Dec 21, 2017

Diabetes, Type 1 Trial in New York, Portland, Seattle (IL-2, Rapamycin)

Completed
  • Diabetes Mellitus, Type 1
  • New York, New York
  • +2 more
Feb 6, 2017

Metastatic Renal Cell Carcinoma Trial in Lebanon (DC vaccine, Bevacizumab, IL-2)

Terminated
Has Results
  • Metastatic Renal Cell Carcinoma
  • DC vaccine
  • +3 more
  • Lebanon, New Hampshire
    Dartmouth-Hitchcock Medical Center
Oct 28, 2015